What is GLP-1 therapy and how does it help with weight loss?

GLP-1 receptor agonists like semaglutide and tirzepatide reduce appetite and slow gastric emptying to support medically supervised weight loss. They require a prescription and provider evaluation — they are not appropriate for everyone.

How much does the medical weight loss program cost?

Programs start at $149/month — all-inclusive with no hidden fees and free shipping. Cost details are discussed during the provider consultation.

Does Sarasota Trim Clinic have a physical office?

No. Sarasota Trim Clinic is a telehealth service. There is no public walk-in office. Consultations, prescriptions, and medication delivery all happen remotely.

Is a prescription guaranteed after signing up?

No. Prescription medication is only provided when a licensed provider determines it is medically appropriate based on your individual health evaluation.

Patient Education

Tirzepatide Patient Education: Forms and Safety Topics

This educational guide introduces tirzepatide terminology, medication forms, and safety topics for discussion with your healthcare provider. For local consultation access and the telehealth process, see our Tirzepatide in Sarasota page.

Discuss with a Provider

The Unique Mechanism of Tirzepatide

Unlike older medications that target a single receptor, tirzepatide is a dual agonist. It targets both the GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors. This combined approach has a synergistic effect on the brain’s regulation of appetite and the body's metabolic function, leading to delayed gastric emptying and powerful satiety signals.

FDA-Approved vs. Compounded Tirzepatide

Tirzepatide is the active ingredient found in two highly recognized FDA-approved brand medications: Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management).

Critical Note on Compounding

When shortages occur, pharmacies may produce compounded tirzepatide. It is important to know that compounded tirzepatide is NOT FDA-approved. The FDA does not review these compounded formulations for safety, efficacy, or consistent manufacturing quality like they do with brand-name versions.

Clinical Evidence and Prescribing Criteria

Clinical trials for FDA-approved tirzepatide formulations have shown highly significant results for weight reduction among eligible patients when combined with lifestyle interventions. Providers assess whether this advanced dual-action mechanism is necessary or suitable for your specific case.

Typical Patient Profile

Generally, candidates for weight management prescriptions have a BMI of:

30 kg/m² or greater (obesity), OR
27 kg/m² or greater (overweight) with at least one co-occurring health condition such as hypertension or elevated cholesterol.

Potential Side Effects and Risks

Because tirzepatide affects the gastrointestinal system, side effects are common, especially when first starting or increasing the dose.

Common Side Effects

• Nausea and Vomiting
• Diarrhea or Constipation
• Indigestion (dyspepsia)
• Stomach pain
• Injection site reactions

Serious Risks

• Risk of thyroid C-cell tumors
• Pancreatitis
• Severe gastrointestinal disease
• Acute gallbladder disease

You must have a thorough discussion with a provider regarding your complete medical history before initiating tirzepatide.

Important Safety Warnings

Tirzepatide is contraindicated for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

If you develop severe, unyielding abdominal pain that may radiate to the back, with or without vomiting, stop the medication and seek emergency medical care.

Sources and Attribution

Information adapted from FDA label approvals, NIH resources, and standard clinical guidelines for dual GLP-1/GIP receptor agonists.

Explore Further

Tirzepatide in Sarasota →Compare Medications →Understanding Side Effects →Safety Information →Eligibility Details →

Medical Disclaimer: This page provides general education and does not replace personalized medical advice. Tirzepatide is a prescription medication requiring formal clinical evaluation.

MEDICAL SOURCES & FURTHER READING

These sources address the topics identified below. They provide general education, not individualized medical advice, a clinic endorsement or a prediction of your results. Prescription treatment requires evaluation by a licensed provider; eligibility, medication and dosing depend on individual circumstances.

U.S. Food and Drug Administration
Zepbound prescribing information and Medication Guide (PDF)
Tirzepatide indications, dual GIP/GLP-1 mechanism, contraindications and adverse reactions; this label does not apply to compounded products.
NIH — National Institute of Diabetes and Digestive and Kidney Diseases
Prescription Medications to Treat Overweight & Obesity
Weight-management medication eligibility, appetite, lifestyle support and individualized treatment decisions.
U.S. Food and Drug Administration
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Lack of FDA approval for compounded drugs, dosing errors, quality concerns and limits on compounding.

RESEARCH & REFERENCES

Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.; SURMOUNT-1 Investigators · New England Journal of Medicine · 2022
Research published in the New England Journal of Medicine reported weight reduction across the tirzepatide groups during a 72-week trial with lifestyle intervention. Results depended on the trial regimen and population, do not establish compounded-product equivalence, and are not a clinic outcome or a guarantee.